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STAT3Interleukin-6 is one of the most prominent triggers of inﬂammatory processes. We have shown recently that
heteroarylketones (HAKs) interfere with stimulated interleukin-6 expression in astrocytes by suppression of
STAT3 phosphorylation at serine 727. Surprisingly, this effect is not based on the inhibition of STAT3-relevant
kinases. Therefore, we here used the structurally modiﬁed HAK compound biotin-HAK-3 in a reverse chemical
approach to identify the relevant molecular target in UV-mediated cross-linking experiments. Employing
streptavidin-speciﬁc 2D-immunoblotting followed by mass spectrometry we identiﬁed nine proteins putatively
interacting with biotin-HAK-3. After co-immunoprecipitation, co-immunoﬂuorescence, surface plasmon reso-
nance analyses and RNAi-mediated knock-down, the eukaryotic elongation factor 1A1 (eEF1A1) was veriﬁed
as the relevant target of HAK bioactivity. eEF1A1 forms complexes with STAT3 and PKCδ, which are crucial for
STAT3S727 phosphorylation and for NF-κB/STAT3-enhanced interleukin-6 expression. Furthermore, the intracel-
lular HAK accumulation is strongly dependent on eEF1A1 expression. Taken together, the results reveal a novel
molecular mechanism for a non-canonical role of eEF1A1 in signal transduction via direct modulation of
kinase-dependent phosphorylation events.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Tissue injury or infectious conditions induce a well-controlled acute
inﬂammatory response to activate the immune system [1,2]. This
process (i) helps to alleviate tissue damage and the spreading of
infectious agents, (ii) contributes to the removal of damaged tissue
and pathogens and (iii) supports systemic repair processes [3,4]. In
contrast, chronic inﬂammation is triggered by cellular stress caused by
age, obesity, diet and smoking as well as physical and emotional stress
[5–9]. This type of inﬂammation contributes to the pathogenesis of
arthritis, heart disease, cancer, chronic lower respiratory disease,tone; SPR, surface plasmon res-
lectric focusing; LC–ESI-MS/MS,
age mass spectrometry; HPLC,
o-dimensional polyacrylamide
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ights reserved.bowel disease, Alzheimer's disease and diabetes [10–17]. Chronic
inﬂammation, once initiated, can persist undetected for a long period
of time and propagate deleterious mechanisms. One of the most prom-
inent triggers of this process is the pleiotropic cytokine interleukin-6
(IL-6) [18–23]. Especially in rheumatoid arthritis, Castleman's diseases,
vascular dementia, Alzheimer's disease and Crohn's disease elevated
levels of this cytokine play a pivotal role in the initiation and progres-
sion of disease [24–28]. The identiﬁcation of general mechanisms
of chronic inﬂammation-associated diseases is of particular clinical
interestwith respect to thedevelopment of novel therapeutic strategies.
Under long-term treatment conditions drugs such as cyclooxygenase
inhibitors and opioids are associated with severe side effects [13].
Therefore, direct blocking of IL-6-mediated signaling presents a promis-
ing strategy for treatment of pathophysiological processes based on
cellular stress-induced chronic inﬂammation. Strong evidence for the
usefulness of this therapeutic approachwas derived from the successful
treatment of patients suffering from juvenile idiopathic and adult
rheumatoid arthritis with Tocilizumab, a humanized monoclonal anti-
body against the IL-6 receptor [29,30]. Blocking the IL-6-mediated
trans-signaling by Tocilizumab slows down the progression of the
disease and improves physical functions of patients.
Recently, we have identiﬁed heteroarylketone (HAK) compounds
as effective small-molecule inhibitors of IL-6 expression in different
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lar mechanism, we have established a cell-basedmodel of oncostatin M
(OSM)-induced IL-6 expression in humanU343 glioma cells. Thismodel
allowed to reveal that HAK compounds selectively suppress the OSM-
mediated phosphorylation of STAT3 at serine 727 and, thereby, counter-
act IL-6 expression. However, the relevant molecular target of HAK
compounds is still unknown.
Therefore, in the present study a trifunctional, chemically-modiﬁed
HAK compound was synthesized to identify the IL-6-relevant target by
a reverse chemical approach. This technique of target screening is
based on UV-mediated covalent cross-linking of a small molecule
effector to target protein(s) followed by biotin moiety-based sorting
or detection of the effector/target complex [32]. In our experimental
system a novel trifunctional screening compound (biotin-HAK-3) was
generated, functionally characterized and used for the identiﬁcation
of the IL-6-relevant molecular target of HAK compounds. Using
streptavidin-speciﬁc 2D electrophoretic immunoblotting followed by
mass spectrometry, we identiﬁed a set of putative HAK binding proteins
from human U343 glioma cells. Based on the results from different cell
based assays and surface plasmon resonance (SPR) we demonstrate
that one of the proteins identiﬁed, the eukaryotic elongation factor-
1A1 (eEF1A1), represents the IL-6-relevant molecular target of the
HAK compound. In addition to its well-known role as a major transla-
tional factor [33] we establish solid evidence for a direct involvement
of eEF1A1 in signal transduction by forming complexes with STAT3
and PKCδ. The resulting eEF1A1-dependent STAT3 phosphorylation
at serine 727 is crucial for NF-κB/STAT3 complex formation and sub-
sequent IL-6 expression in astrocytoma cells stimulated with OSM.
These results provide further evidence for the described multi-
functionality of eEF1A1 (moonlighting protein) to be not only responsi-
ble for the ribosomal aa-tRNA transport but also implemented in cellular
cascades regulating gene expression, mRNA transport, cell growth and
the cytoskeletal network dynamics [34]. The novel mechanism identi-
ﬁed here may be the basis for the development of novel strategies
for targeting pathological IL-6-driven chronic inﬂammation by HAK-
mediated modulation of eEF1A1 bioactivity.
2. Materials and methods
2.1. Synthesis of trifunctional compounds
Trifunctional compound composed of (i) a moiety with IL-6-
lowering activity, (ii) a biotin-tag for puriﬁcation and labeling purposes
and (iii) a photo-reactive group allowing cross-linking of bound
proteins was prepared as drawn in Scheme 1. The benzothiazole deriv-
ative was prepared by means of a metalation reaction starting from the
Weinreb amide (step a). Prolongation of the chain by a coupling
reaction leads to the ﬁnal benzothiazole compound (step e).
All compounds containing an azido-moiety were handled in dark
ﬂasks or vials andwere puriﬁed in a dark room to protect the compound
from degradation. The ﬁnal puriﬁcation step was performed on an
analytical HPLC. The retention time of the product was determined by
taking fractions into dark vials directed by the UV detector and MS
analyses, followed by 3 micro-preparative HPLC runs without a UV
detector. The fractions were taken according to the pre-determinedScheme 1. aReagents and conditions: (a) benzothiazole, n-BuLi, THF, −78 °C, 45 min;
(b) TFA, CH2Cl2, rt., 2.5 h; (c) TFA*H-L-Leu-BT, TOTU, ethyl (hydroxyimino)-cyanoacetate,
NMM, DMF, rt., 2 h; (d) TFA, CH2Cl2, rt., 2.5 h; (e) isobutyl chloroformate, NMM, TFA*H-
para-azido-L-Phe-L-Leu-BT, THF, -15 °C, 16 h.time. The negative control substance biotin-HAK-3/ΔBTh was
prepared via peptide solid phase strategy with Fmoc-protected on
a SASRIN™-resin.
2.2. Cell line and culture conditions
The human glioma cell line U343 [35] was maintained in DMEM
containing 10% fetal bovine serum and 60 μg/ml gentamycin
(Life Technologies) at 37 °C in a 10% CO2 atmosphere.
2.3. Quantitative real-time PCR
Total RNA of cultured U343 glioma cells was isolated using RNA
isolation kit “NucleoSpin RNA II” from Macherey and Nagel (Düren).
RNA quantity was measured spectrophotometrically (NanoDrop 2000,
Peqlab) and 0.5 μg of total RNA was transcribed into cDNA using
Superscript III and oligo-dT primer (Life Technologies). Quantitative
real-time PCR (qRT-PCR) was performed with QuantiFast SYBRGreen
PCR Master Mix (Qiagen) using the Rotorgene 3000 system (Qiagen).
Gene expression was normalized to the expression of four reference
genes glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 5′-ACCC
AGAAGACTGTGGATGG-3′; 5′-TTCTAGACGGCAGGTCAGGT-3′), glucose-
6-phosphate dehydrogenase (G6PDH; 5′-ATCGACCACTACCTGGGC
AA-3′; 5′-TGCAGTAGGTGGTTCTGCAT-3′), hypoxanthine-guanine
phosphoribosyltransferase (HPRT; 5′-TGCTGACCTGCTGGATTACA-3′;
5′-CCTGACCAAGGAAAGCAAAG-3′) and tissue inhibitor of metallopro-
teinase 1 (TIMP-1; 5′-AATTCCGACCTCGTCATCAG-3′; 5′-GTTGTGGGAC
CTGTGGAAGT-3′). Primers for eEF1A1 (5′-TCTGGTTGGAATGGTGACAA-
3′; 5′-ACGAGTTGGTGGTAGGATGC-3′) and IL-6 (5′-AGTGAGGAACAAGC
CAGAGC-3′; 5′-GAGGTGCCCATGCTACATTT-3′) were designed using the
Primer3 Software (http://frodo.wi.mit.edu/). Data were analyzed by
Rotorgene 3000 Software version 6.0 by comparative quantitation. The
quality of appropriate PCR products was conﬁrmed by melting curve
analysis and agarose gel electrophoresis.
2.4. ELISA
Measurement of IL-6 in conditioned mediumwas done by means of
human-speciﬁc IL-6 Cytoset kits (Life Technologies) according to the
manufacturer's protocol. From each sample, 20 μl of conditioned
medium was analyzed in duplicate.
2.5. Preparation of whole cell extracts
After treatment, human U343 cells were lysed with cell lysis buffer
(Life Technologies) supplementedwith 0.2 mg/ml sodiumorthovanadate
(Sigma), protease inhibitor mix complete mini (Roche) and 1mM AEBSF
(Sigma) for 30 min on ice. Lysates were centrifuged for 15 min at
15,000 ×g and 4 °C and stored at−20 °C. Protein content in supernatants
was quantiﬁed by Bradford assay (Sigma) according to the manufac-
turer's protocol.
2.6. Western blotting
Western blotting was performed with 30 μg protein of whole cell
extracts, mixed with 4× SDS sample loading buffer (Life Technologies)
and denatured for 10 min at 85 °C. Cell extracts separated by 4–12%
Novex Bis-Tris Mini Gel system (Life Technologies) were transferred
to Roti-NC nitrocellulose membranes (Roth) and probed with primary
antibodies against PKCδ (#8402, Santa Cruz Biotechnology), STAT3
(#9132) and P-STAT3S727 (#9134 from Cell Signaling). The detection
of biotinylated proteins was carried out using HRP-conjugated
streptavidin (Sigma). To conﬁrm equal loading and blotting of protein
samples membranes were subsequently probed with an antibody
against α-tubulin (Sigma). Proteins were visualized using HRP-
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SuperSignal West Pico system (Thermo Fisher Scientiﬁc).
2.7. Small interfering RNA (siRNA) and oncostatin-M treatment
Human U343 cells (0.25 × 106 cells/well) were seeded in 24 well
plates (Greiner) and treated immediately with 2.5 μl distilled water
(mock), or transfected with 100 nM non-target control (NTC, Thermo
Fisher scientiﬁc) or eEF1A1-speciﬁc siRNA pools (#35265, Santa Cruz
Biotechnology) using DharmaFECT 1 siRNA transfection reagent
(Thermo Fisher Scientiﬁc) according to the manufacturer's protocol.
This procedure was demonstrated to have several signiﬁcant advan-
tages over identical screens with the corresponding individual siRNA
duplexes such as greater phenotypic penetrance for siRNA pools than
for the parental individual duplexes and greater likelihood of generating
loss-of-function phenotypes than individual siRNA duplexes [36]. After
48 h adherent cells were transfected a second time under identical
conditions for further 24 h and subsequently stimulated with OSM
(100 ng/ml; PeproTech) for additional 6 h.
2.8. Immunocytochemistry
Human U343 cells (1 × 105 cells/well) were grown on cover slips in
24well plates (Greiner). After the time of treatment indicated cellswere
ﬁxed in ice-cold methanol for 10 min on ice, and then incubated with
antibodies against STAT3 (#9132), P-STAT3S727 (#9134; Cell Signaling),
eEF1A1 (#05-235; Millipore), PKCδ (#8402; Santa Cruz Technology)
and MPR (#444105; Calbiochem) overnight at 8 °C. Subsequently,
cells were incubated with the appropriate ﬂuorescence-conjugated
secondary antibody (Dianova) at room temperature for 45 min. For
detection of biotinylated proteins, ﬁxed andwashed cells were incubat-
ed directly with Cy3-conjugated streptavidin (Dianova) for 90 min at
room temperature. Finally, all coverslips were mounted on microscope
slides with Fluorescence Mounting Medium (Dako) and analyzed by a
ﬂuorescence microscope (Axiovert S100; Carl Zeiss) equipped with a
CCD camera (SPOT, visitron systems) and Achroplan objectives. Image
acquisition was performed with MetaMorph Image Analysis Software
(release 4.6.5; visitron systems).
2.9. Immunoprecipitation
Cell lysates from 4 × 106 U343 cells/sample were obtained as
described above. For biotin-speciﬁc immunoprecipitation 300 μg of
total proteinwas incubatedwith 40 μl streptavidin-conjugatedmagnet-
ic beads (Life Technologies) or distilled water (control) for 1 h at 4 °C.
For eEF1A1-speciﬁc co-immunoprecipitation 250 μg of total protein
was immunoprecipitated with 2 μg mouse anti-eEF1A1 antibody
(Millipore) or distilled water (control) overnight at 4 °C. Immuno-
precipitated samples were incubated with 20 μl Dynabeads Protein G
(Thermo Fisher Scientiﬁc) for 1 h at 4 °C. Streptavidin- and protein
G-conjugated beads were washed 3 times with 1 ml PBS. Preparation
of samples for SDS-PAGE analysis was done by means of dilution with
SDS-PAGE sample buffer (Life Technologies), followed by denaturation
at 90 °C for 10 min. SDS-PAGE analyses were performed as described
above.
2.10. Two-dimensional electrophoresis (2-DE)
The 2-DE analysis was performed by the Proteome Factory (Proteome
Factory AG; http://www.proteomefactory.com) based on the protocol
by Klose and Kobalz [37]. The sample was solved in 7 M urea, 2 M
thiourea, 2% carrier ampholytes and 70 mM DTT. After centrifugation
(10,000 ×g, 30 min, room temperature) the cleared supernatant
was transferred to a new reaction tube. Isoelectric focusing (IEF; ﬁrst
dimension) was performed in vertical rod gels containing 9 M urea,
4% acrylamide, 0.3% piperazine diacrylamide, 5% glycerine, 2% carrierampholyte (pH 2–11), 0.06% TEMED and 0.08% ammonium persulphate.
The total amount of 30 μg of protein was processed and focussed
at 1841 Vh. Subsequently, IEF gels were incubated in a buffer containing
125mMTris-phosphate (pH 6.5), 40% glycerol, 65mMDTT and 3% SDS
for 10 min. After this equilibration step, SDS-PAGE (second dimension)
was carried out in gels [0.1 cm × 7 cm × 8 cm; 15% acrylamide, 0.2%
bisacrylamide, 375 mM Tris–HCl (pH 8.8), 0.1% SDS, 0.03% TEMED,
0.08% ammonium persulphate]. Frozen IEF gels were thawed, applied
to SDS gels, and covered with 0.5% agarose. Electrophoresis was run
at 150 V and 30 mA for 75 min. Two replicate 2-DE separations were
performed for localization of biotinylated proteins. One gel was stained
with Coomassie (Proteome Factory PS-2002) for preparative applica-
tions; the other gel was used forWestern blotting to detect biotinylated
target proteins. For biotin-speciﬁc immunostaining membranes were
probed with HRP-conjugated streptavidin for 1 h at room temperature
followed by visualization of proteins with the SuperSignal West Pico
system (Thermo Fisher Scientiﬁc).
2.11. Identiﬁcation of 2-DE separated proteins
Protein identiﬁcation using nano-LC–ESI-MS/MS was performed by
the Proteome Factory (Proteome Factory AG). The MS system consists
of an Agilent 1100 NanoLC system (Agilent), PicoTip emitter (New Ob-
jective) and an Esquire 3000 plus ion trap MS (Bruker). Protein spots
were in-gel digested using trypsin (Promega) and applied on a column
(Zorbax SB C18, 0.3 mm_5 mm, Agilent) using 1% acetonitrile/0.1%
acetic acid for 5 min. Desalted peptides were applied on a column
(Zorbax 300 SB C18 column, 75 mm_150 mm, Agilent) and separated
through a gradient reaching from 5% acetonitrile/0.1% acetic acid to
40% acetonitrile/0.1% acetic acid within 40 min. MS spectra were
automatically taken by Esquire 3000 plus according to manufacturer's
instrument settings for nano-LC–ESI-MS/MS analyses. Proteins were
identiﬁed using MS/MS ion search of MASCOT search engine (Matrix
Science) and nr protein database (National Center for Biotechnology
Information, Bethesda, MD). MASCOT expresses the probability that
peptides match at random to a given protein by a probability score. A
score larger than 57 indicates identity or extensive homology (p b 0.05).
2.12. Enrichment of endogenous eEF1A1 protein
Adherently grown U343 glioma cells were harvested by trypsin
treatment. Cells were suspended in 500 μl PBS and disrupted by repeat-
ed freeze thaw cycles. One tablet of Complete Mini Protease Inhibitor
Cocktail (Roche) was added to 5 ml buffer to prevent proteolytical deg-
radation. After centrifugation at 15,300 ×g for 20 min at 4 °C the super-
natantwas dialyzed overnight against 10mMHEPES pH8.0. The sample
was then applied to a SP-sepharose column (1 × 5 cm, Amersham
Biosciences) equilibrated in 10 mM HEPES pH 8.0 and eluted with a
linear gradient of 0 to 1 M NaCl in the same buffer. Collected fractions
were analyzed by SDS-PAGE and Western blot. Before application to
surface plasmon resonance measurements, the eEF1A1 containing
fractions were concentrated tenfold by using Centricon 10 kDa
(Millipore). The eEF1A1 protein concentration of the sample was
estimated by densitometric analysis and used for calculation of the
dissociation constant. The total yield was about 1.2 mg eEF1A1 protein
extracted from 1.5 × 109 U343 cells.
2.13. Surface plasmon resonance (SPR) analysis
In vitro binding studies were performed by Surface Plasmon
Resonance (SPR). Initially, Biotin-HAK-3 and Biotin-HAK-3/ΔBTh
compounds (1 μM each) were separately immobilized on the surface
of streptavidin-coated chips (Sensor Chip SA, BR-1003-98) using a bio-
sensor BIAcore 3000 instrument (BIACOREAB). After that the streptavidin
on the chip surfacewas saturatedwith biotin followed by awashing step.
Typically, 250 resonance units (RU) of each biotinylated compoundswere
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protein fraction (5.8 μM) solved in running buffer (HBS-EP; pH 7.4,
BIACORE AB) was injected with a ﬂow rate of 30 μl/min over 180 s. The
dissociation phase was monitored for 300 s. Data were analyzed and
calculated with the program BIAevaluation (BIACORE AB).
2.14. Statistical analysis
Values are expressed as mean ± SD. Standard unpaired t test and
one-sample t test were performed for analyses of statistical signiﬁcance
using GraphPad Prism version 4.00 for Windows, GraphPad software,
San Diego California USA, www.graphpad.com. Differences between
treatments were considered signiﬁcant when p b 0.05.
3. Results
3.1. Effect of HAK compounds on STAT3S727-related kinases
Recently, we have shown that HAK compounds selectively suppress
the OSM-mediated phosphorylation of STAT3 at serine 727 and thereby
antagonize the induction of IL-6 expression [31]. However, the relevant
molecular target of HAK compounds responsible for this bioactivity is
still unknown. There are a number of kinases described to be involved
in the STAT3 phosphorylation at serine 727 [38]. To investigate possible
kinase inhibitory effects of HAK compounds in vitro kinase assays were
performed (Cerep, France). HAK compounds did not inhibit any of
the kinases tested (Akt1, PKCδ, CDK1, ERK1/2, JNK1, p38a, MEK1,
RSK2). Therefore, we conclude that the IL-6-lowering bioactivity of
HAK compounds is not primarily based on STAT3S727-related kinase
inhibition, but rather on the modulation of another cellular target.
3.2. Synthesis of the trifunctional compounds
For a more detailed investigation of the mode of action of HAKs and
to identify the molecular target involved in the regulation of IL-6 ex-
pression the trifunctional compound Boc-L-Lys(biotin)-L-Phe(p-N3)-L-
Leu-benzothiazole was generated (Fig. 1). To assure a similar mode of
action as revealed in former studies the benzothiazole moiety (C) was
kept as an essential part of this compound. Beside this aromatic moiety
for the initial interaction a biotin label (A) and an azido-phenylalanine
(B) moiety are components of the generated molecule. By means of
an appropriate stimulation, the azido-phenylalanine forms a covalentFig. 1. Structure of the trifunctional compound Boc-L-lys(biotin)-L-phe(p-N3)-L-leu-benzothiazo
where the lysine was substituted by a biotinylated lysine (A). For UV-mediated cross-linking o
The negative control compound biotin-HAK-3/ΔBTh lacks the benzothiazole moiety (C) responbond via a highly reactive nitrene intermediate. Furthermore, the
biotinylated lysine was placed within the molecule to allow an inter-
action with an appropriate modiﬁed streptavidin-containing antipode.
To address the inﬂuence of the heteroaromate on biological activity a
comparative compound missing the benzothiazole was prepared as
a negative control. In that case the C moiety is represented as OH
(Fig. 1) and will be abbreviated as biotin-HAK-3/ΔBTh.
3.3. Characterization and validation of trifunctional compounds
Chemical modiﬁcations of well characterized parental compounds
must be considered with caution, because they could have an effect on
bioactivity. Therefore, the HAK-3-based derivatives biotin-HAK-3 and
biotin-HAK-3/ΔBTh were characterized concerning their potency to
inhibit OSM-induced IL-6 mRNA (Fig. 2A) and protein (Fig. 2B) expres-
sion in human U343 cells. In accordance with previous results the
trifunctional compound biotin-HAK-3 (40 μM) is bioactive, while
benzothiazole-lacking compound biotin-HAK-3/ΔBTh, designed as
negative control, is not.
In order to reveal the intracellular interaction partner(s) and to
identify the molecular target of biotin-HAK-3, in a ﬁrst step, the sub-
cellular distribution of biotin-HAK-3 was revealed by highly speciﬁc
biotin/streptavidin-based immunocytochemistry. U343 cells were
co-treated for different periods of time as indicated with OSM
(100 ng/ml) and biotin-HAK-3 or biotin-HAK-3/ΔBTh (40 μM, each).
After subsequent UV-mediated cross-linking (10 min, 350 nm) and
methanol ﬁxation, intracellular biotin was labeled by Cy3-conjugated
streptavidin. Interestingly, the compound biotin-HAK-3 displayed
an inhomogeneous cellular distribution pattern mainly localized to
the perinuclear space, which accumulated over time (Fig. 2C). Such a
distribution pattern was never observed in U343 cells treated with the
inactive control compound biotin-HAK-3/ΔBTh. Only marginal staining
of U343 cells was observed, which was not time-dependent and most
likely derived from endogenous biotinylated proteins like carboxylases.
Thus, the benzothiazol group is essential for both the bioactivity and the
subcellular localization of biotin-HAK-3. This result strongly indicates
that the cellular localization of biotin-HAK-3 is closely related to the
IL-6-relevant molecular target of HAK-3 compounds. Furthermore, it is
quite interesting, that the biotin-HAK-3-mediated staining pattern
displays peak intensity at 6 h post-OSM stimulation and fades almost
completely after 24 h. This is consistent with the recently published
observation that the IL-6-relevant molecular target of HAK compoundsle (biotin-HAK-3). Biotin HAK-3 is structurally based on the parenteral compound HAK-3,
f compound/target complexes the para-azido-L-phenylalanine group (B) was introduced.
sible for the bioactivity of HAK compounds. Boc = tert.-butyloxycarbonyl.
Fig. 2. Bioactivity and subcellular localization of biotin-HAK-3. The trifunctional compound biotin-HAK-3 inhibits OSM-stimulated IL-6mRNA expression (A) and IL-6 secretion (B) to the
same extent as the parental compoundHAK-3. The negative control compound biotin-HAK-3/ΔBTh did not possess this inhibitory activity. For IL-6 analyses cellswere cultivated in 24well
plates for 24 h. Afterwards, cells were stimulated with OSM (100 ng/ml) and treated with vehicle (Co), biotin-HAK-3 and biotin-HAK3/ΔBTh (40 μM) as well as HAK-3 (20 μM) for 6 h.
Expression level of IL-6mRNAwasmeasured by qRT-PCR, while conditionedmediawere used for quantiﬁcation of IL-6 release by ELISA. Themean IL-6 protein concentrationmeasured in
OSM-stimulated controls was 1270.6 pg/ml. (C) Subcellular distribution of biotin-HAK-3 and biotin-HAK-3/ΔBTh in U343 cells. For immunocytochemistry cells were cultivated on cover
slides and co-treated with OSM (100 ng/ml) and biotinylated HAK compounds (40 μM) for the time indicated. After methanol ﬁxation at time points indicated the biotin-label was de-
tected by Cy3-conjugated streptavidin. (D) Co-localization of biotin-HAK-3 with the late endosome marker mannose 6-phosphate receptor (MPR). Using the identical experimental
set-up, after 6 h of treatment, cellswere labeled in parallelwith Cy3-conjugated streptavidin (redﬂuorescence) andwith speciﬁc antibody toMPR (greenﬂuorescence). ns, not signiﬁcant;
**p b 0.01; ***p b 0.001.
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to 6 h post-stimulation [31].
To specify the perinuclear localization of biotin-HAK-3 in more
detail, co-localization experiments were performed with selected cell
compartment-speciﬁc markers by double ﬂuorescence labeling andFig. 3. Detection of biotin-labeled proteins. (A) Streptavidin-speciﬁc immunoblotting of biotiny
with OSM (100 ng/ml) and biotin-HAK-3 (40 μM) for 6 h. After UV cross-linking and cell lys
streptavidin. Cell homogenates treated with biotin-HAK-3/ΔBTh or vehicle (Co) served as n
dimensional electrophoresis followed by streptavidin-speciﬁc immunoblotting.confocal laser scanning microscopy. Only the late endosome marker
protein mannose-6-phosphat-receptor (MPR) displayed an almost
complete co-localization strongly indicating an association of biotin-
HAK-3-target with structural components present in late endosomes
(Fig. 2D). There was also a partial co-localization of biotin-HAK-3 withlated proteins separated by one-dimensional electrophoresis. U343 cells were co-treated
is homogenates (30 μg/lane) were analyzed by immunoblotting using HRP-conjugated
egative controls. (B) Separation of the biotin-HAK-3-treated cell homogenate by two-
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(Supplementary Fig. 1).
To identify themolecular target responsible for the IL-6 bioactivity of
HAK compounds a sufﬁcient and selective in situ labeling of proteins by
the biotin-HAK-3 screening compound had to be validated. Therefore,
U343 cells were stimulated with OSM (100 ng/ml) and co-treated
with 40 μM biotin-HAK-3 or biotin-HAK-3/ΔBTh for 6 h followed by
UV-mediated covalent cross-linking for 10 min at 350 nm. In a ﬁrst
experimental setup employing afﬁnity chromatography or streptavidin-
mediated immunoprecipitation the separation of biotin-labeled proteins
from U343 cell homogenate did not result in a selective and sufﬁcient
enrichment of in situ-labeled proteins necessary for subsequent mass
spectrometry. In an alternative approach SDS-PAGE was combined with
streptavidin-speciﬁc immunoblotting to detect and pick up biotinylated
proteins for MS analysis. As shown in Fig. 3A clear biotin/streptavidin-
dependent signals were detected under denaturating conditions.
Protein bands at approximately 62 and 98 kDa were consistently
observed in all three types of cell homogenates investigated (vehicle,
biotin-HAK-3/ΔBTh, biotin-HAK-3). Therefore, the detection of these
bands as false-positives is most likely based on endogenous biotin-
containing proteins likemembers of the carboxylase family. Important-
ly, only in the biotin-HAK-3-treated cell homogenate there were
additional biotin-speciﬁc signals detectable. This highly selective in
situ labeling pattern by biotin-HAK-3 compound strongly correlates
with the results obtained from immunocytochemistry approach as
shown in Fig. 2C. The selective biotin-HAK-3 staining pattern comprises
at least 4 prominent (at approximately 50, 55, 60 and 80 kDa) and 6
weak protein bands possibly including the relevant molecular HAK
target.
3.4. Identiﬁcation of putative molecular targets of HAK compounds
The characterization of trifunctional compounds demonstrated the
applicability of the biotin-HAK-3 compound as a tool to identify puta-
tive HAK-interaction partners. This compound is bioactive and speciﬁ-
cally biotinylates protein targets, while negative control compound
biotin-HAK-3/ΔBTh did not. Based on this result, biotin-HAK-3-treated
U343 cell homogenate was ﬁrst separated by 2D-PAGE followed by
mass spectrometry of biotin-labeled protein dots. Cell homogenate of
biotin-HAK-3/ΔBTh-treated cells was used as a negative control to
identify false-positive results. In Fig. 3, a representative immunoblot
for biotin-HAK-3-labeled homogenate (B) separated by 2D-PAGE is
shown. Spots of interest were prepared by in-gel trypsin-mediated
digestion and analyzed by nano-LC–ESI-MS/MS. Finally, identiﬁcation
of putative biotin-labeled proteins was carried out via automated
database searching against protein database of National Center of
Biotechnology Information. A total number of 16 different proteins
were obtained from biotin-HAK-3 homogenates with a score higher
than 57, provided byMASCOT default at 5%. However, seven of the iden-
tiﬁed proteins had to be excluded asmolecular HAK targets because they
were also detected in the HAK-3/ΔBTh-treated control sample (Table 1).
Interestingly, no endogenous biotin-dependent carboxylases were
identiﬁed as obvious false positive interaction partners.
The existing literature was searched to get hints on known inter-
actions of the 9 remaining screening hits with the activation of STAT3
signaling cascade. We have recently shown that the molecular trigger
of HAK anti-IL-6-bioactivity is most likely a selective suppression of
STAT3 phosphorylation at serine 727. Interestingly, for only one of
these remaining hits, the eukaryotic translation elongation factor 1A1
(eEF1A1) protein, supporting data were found, pointing out a possible
role of eEF1A1 in STAT3 activation. Namely, the protein kinase Cδ
(PKCδ) known to be associated with the IL-6 family receptor complex
[39] is described to interact with STAT3 and eEF1A1 [38,40]. Further-
more, eEF1A1 is known to form complexes with SH2 domains of
different signaling molecules like Shp1 and Shp2 strongly suggesting
an interaction also with the SH2 domain of STAT3.Based on this cascade, we hypothesized that eEF1A1, STAT3 and
PKCδmight form a ternary complex regulating IL-6 receptor-mediated
STAT3 phosphorylation. Therefore, in a ﬁrst step, co-localization and
co-immunoprecipitation studies were performed with U343 cells
stimulated with OSM for 6 h. Results obtained from immunocyto-
chemistry (Fig. 4A) and co-immunoprecipitation (Fig. 4B) analyses
clearly demonstrate eEF1A1 co-localization with PKCδ and STAT3 in
the perinuclear space and cellular processes and the interaction of
eEF1A1 with PKCδ and STAT3.
Additionally, the physical association of PKCδ and STAT3 with
eEF1A1 was demonstrated by streptavidin-speciﬁc immunoprecipita-
tion/Western blot analysis of biotin-HAK-3-treated U343 cells stimulat-
ed with OSM for 6 h (Fig. 4C) because only eEF1A1-associated proteins
can be detected under these experimental conditions. In contrast,
ﬁlamin A, a putative interaction partner of biotin-HAK-3 (Table 1) but
not described to interact with STAT3S727 phosphorylation cascade and
α-tubulin used as a negative control, were not detected by this procedure
(Fig. 4C). These results strongly support our hypothesis that all three
proteins are associated and act together in a complex regulating the
gp130/OSMRβ receptor-mediated signaling.
3.5. Characterization of biotin-HAK-3/eEF1A1 interaction
In a further step to validate eEF1A1 as the physiologically relevant
target of HAK compounds, the molecular interaction between biotin-
HAK-3 and eEF1A1 was investigated. Endogenous eEF1A1 protein was
puriﬁed fromU343 cells treated with OSM for 6 h. In Fig. 5A a represen-
tative silver-stained PAGE and a Western blot analysis demonstrating
the enrichment of eEF1A1 protein for SPR analysis are shown.
The ligand biotin-HAK-3 was immobilized on a streptavidin sensor
chip with 250 response units. Free biotin binding sites on the chip
were saturated by the addition of biotin after the incubation with bio-
HAK-3. The eEF1A1-enriched fraction bound to the immobilized
biotin-HAK-3 on the chip, but not to the immobilized HAK-3/ΔBTh
(Fig. 5B). No unspeciﬁc interactions of the fractions with the
streptavidin sensor chip matrix were observed. These results conﬁrm
the binding speciﬁcity of eEF1A1 protein to biotin-HAK-3 in vitro.
However, the levels of immobilized biotin-HAK3 did not correlate
with observed or extrapolated Rmax values. Therefore, an evaluation of
the obtained sensograms would not lead to actual kinetic binding
constants. Nevertheless, the different sensograms monitoring the inter-
action of eEF1A1 to biotin-HAK-3 and HAK-3/ΔBTh, respectively,
support our hypothesis that HAK compounds target eEF1A1 under
physiological conditions in vivo.
This is further supported by the eEF1A1 expression-dependent
perinuclear localization of biotin-HAK-3-speciﬁc in U343 glioma cells.
In contrast tomock and to non-target control (NTC) samples, the typical
subcellular localization pattern of biotin-HAK-3 was partially lost or
changed dramatically after knockdown of eEF1A1 by siRNA technique
(Fig. 6A). Vice versa, the localization of eEF1A1 is not sensitive to
biotin-HAK-3 treatment (Supplementary Fig. 2). The remaining mRNA
expression level of eEF1A1 was lower than 15% in comparison to
mock and NTC samples (Supplementary Fig. 3).
3.6. Characterization of eEF1A1 as IL-6 relevant target of HAK compounds
Recently, we have characterized HAK compounds as potent
inhibitors of OSM- and LPS-induced IL-6 expression in vitro and
in vivo. To clarify a possible role of eEF1A1 in the regulation of OSM-
mediated IL-6 expression, eEF1A1 was knocked down for 72 h by
siRNA technique in U343 cells followed by OSM treatment for 6 h. The
amounts of IL-6mRNA(Fig. 6B) and protein (Fig. 6C)were subsequently
quantiﬁed by qRT-PCR and ELISA, respectively. Interestingly, the
observed effect of eEF1A1-speciﬁc knockdown was similar to that of
HAK compounds. ThemRNAandprotein levels of IL-6were signiﬁcantly
reduced by 40% (HAK-3, by 50%) and by 70% (HAK-3, by 80%),
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971I. Schulz et al. / Biochimica et Biophysica Acta 1843 (2014) 965–975respectively as compared to mock and NTC samples. These data clearly
show the involvement of eEF1A1 in the OSM-induced IL-6 expression,
which is compromised by HAK compounds.
The stimulation of OSM-induced IL-6 expression in U343 glioma
cells was shown recently to be strongly dependent on HAK-sensitive
STAT3 phosphorylation at serine 727 (pSTAT3S727) [31]. Therefore,
the effect of siRNA-mediated knockdown of eEF1A1 on STAT3S727
phosphorylation was investigated under the identical experimental
setup described above.Western blot analyses revealed a clear inhibition
of OSM-induced STAT3 phosphorylation at serine 727 after eEF1A1
knockdown at the same order of magnitude as HAK compounds
(Fig. 6D). The eEF1A1 knockdown-speciﬁc suppression of OSM-
induced pSTAT3S727 was conﬁrmed by immunocytochemistry. U343
cells grown on coverslips were treated identically as for Western blot
analysis. In Fig. 6E an example of eEF1A1 knockdown-mediated
suppression of nuclear pSTAT3S727 phosphorylation is shown. Nuclear
localization was conﬁrmed by DAPI staining followed by densitometric
analysis of at least 120 nuclei per sample from 3 independent experi-
ments. In comparison to mock and to NTC samples, densitometric anal-
ysis revealed an eEF1A1 knockdown-mediated reduction of STAT3S727
phosphorylation by 60%. This result matches well with the recently
described effect of IL-6 bioactive HAK compounds on pSTAT3S727 by
70%.
Taken together, knockdown of eEF1A1 mimics completely the HAK
compound-speciﬁc suppression of OSM-induced pSTAT3S727 phosphor-
ylation and IL-6 expression, demonstrating that eEF1A1 represents
most likely the relevant molecular target for described IL-6 bioactivity
of HAK compounds.
4. Discussion
Recently, we have characterized HAK compounds as potent
inhibitors of IL-6 expression in vitro and in vivo [31]. Although the
selective suppression of STAT3 phosphorylation at serine 727 was
demonstrated as being the molecular trigger of HAK bioactivity, the
relevant molecular target remained unknown.
Hence, we performed the present study to identify the molecular
target of HAK compounds responsible for the IL-6-lowering effect.
Biochemical assays demonstrated that kinases catalyzing STAT3S727
phosphorylation are not targeted by HAK compounds. Therefore, a
reverse chemical approach using a cell-based model of HAK-mediated
inhibition of OSM-induced IL-6 expression was performed [31]. This
small molecule afﬁnity-based technique allows to pull out covalently
the UV-linked small molecule-target complexes by biotin-mediated
sorting from complex proteome samples [32,41]. The chemically
modiﬁed compound biotin-HAK-3 showed a 50% loss of potency in
comparison to the parenteral compound HAK-3. However, by in-
creasing the experimental concentration from 20 μM to 40 μM the
bioactivity of biotin-HAK-3was fully recovered. In contrast, thenegative
control compound biotin-HAK-3/ΔBTh lacking the bioactivity-related
benzothiazole group did not possess an inhibitory effect at the same
concentration. Immunoﬂuorescence staining of biotin-HAK-3-treated
cells provided an initial indication on the subcellular localization of
the HAK-3 target protein. The perinuclear accumulation of biotin-
HAK-3 with a peak intensity at 6 h post-treatment is in line with the
recently published observation, that the molecular target of HAK com-
pounds is involved in 3 to 6 h post-OSM stimulation at earliest [31].
This strongly indicates, that the observed subcellular localization of
biotin-HAK-3 closely correlates with the IL-6-relevant molecular target
of HAK compounds rather thanwith endogenous biotin-dependent car-
boxylases [42]. Consistently, there is no intracellular time-dependent
accumulation of the negative control compound biotin-HAK-3/ΔBTh.
The subcellular distribution pattern of biotin-HAK-3 co-localized almost
completely with the late endosomemarkerMPR. This strongly indicates
the interaction of biotin-HAK-3 with a target processed by or involved
in the endocytotic pathway. Regarding our discovery of the association
Fig. 4. Complexation of PKCδ and STAT3with eEF1A1. (A) Immunoﬂuorescent double labelings of U343 cells clearly demonstrate eEF1A1 co-localizationwith PKCδ and STAT3 especially in
the cellular processes (arrows). U343 cells were cultivated on cover slips for 24 h followed by treatment with OSM (100 ng/ml) for 6 h. Post-treatment, cells were ﬁxed in methanol and
labeled with speciﬁc antibodies to eEF1A1, PKCδ and STAT3. (B) Co-immunoprecipitation analysis using homogenates from U343 cells showed a complexation of eEF1A1 with PKCδ und
STAT3. Stimulated U343 cells (OSM; 100 ng/ml; 6 h) were lysed and the homogenates were immunoprecipitated with an anti-eEF1A1 antibody or vehicle (control). Immunoblots were
prepared and probed with antibodies against PKCδ und STAT3. (C) Streptavidin-speciﬁc detection of eEF1A1, PKCδ and STAT3 in biotin-HAK-3-labeled cell homogenate. OSM-stimulated
U343 cells were labeled in vivo with biotin-HAK-3, biotin-HAK-3ΔBTh and vehicle (Co) followed by UV cross-linking and cell lysis. Cell homogenates were immunoprecipitated with
streptavidin-conjugated beads followed by Western blot analysis described above. Filamin A and α-tubulin served as negative and loading control, respectively.
972 I. Schulz et al. / Biochimica et Biophysica Acta 1843 (2014) 965–975of the IL-6-relevant target with the gp130/OSMRβ receptor complex
[31], an accumulation of target-bound biotin-HAK-3 in the late
endosomes is likely to occur via ligand-induced receptor internalization
[43].
Mass spectrometry of selectively biotin-HAK-3-labeled proteins
identiﬁed nine putative interaction partners. Based on the literature
eEF1A1 was selected for further analyses. In addition to its canonical
role in protein biosynthesis, eEF1A1 is described to have a number ofFig. 5. Endogenous eEF1A1 from U343 cells binds to immobilized biotin-HAK-3 in vitro. (A) T
(SPR) an eEF1A1-enriched fraction was generated from U343 cell homogenate as described in e
acterized by silver staining and by eEF1A1-speciﬁc immunoblotting. (B) SPR analysiswas perfor
biotin-HAK-3 and biotin-HAK-3/ΔBTh immobilized to a streptavidin sensor chip. A clear binding
ΔBTh-coated surface (lower trace) was detected.non-canonical functions, regulating signal transduction processes
[34,44]. Intriguingly, eEF1A1 interacts with PKCδ [38], an important reg-
ulator of gp130 receptor-mediated gene transcription via STAT3S727
phosphorylation [39,40]. This feature of eEF1A1 ﬁts well with the
physiological function postulated for the unknown IL-6 relevant target
of HAK compounds [31]. For all other putative interaction partners
identiﬁed, there are no explicit references documenting an appropriate
involvement in gp130-mediated STAT3phosphorylation. The literature-o study the interaction between eEF1A1 and biotin-HAK-3 by surface plasmon resonance
xperimental procedures. eEF1A1-enriched fraction was separated by SDS-PAGE and char-
med as described under experimental procedures injecting eEF1A1-enriched fraction over
of eEF1A1 to the biotin-HAK-3 surface (upper trace), but not to the inactive biotin-HAK-3/
Fig. 6. Characterization of eEF1A1 as the IL-6-relevant molecular target of biotin-HAK-3. (A) Dependency of biotin-HAK-3 subcellular localization on eEF1A1 expression. For RNAi-
mediated knockdown of eEF1A1, U343 cells seeded on coverslips were treated with vehicle (mock) or transfected with non-target control siRNA (NTC) or with eEF1A1-speciﬁc siRNA
(si-eEF1A1) followed by OSM stimulation. Knockdown of eEF1A1, veriﬁed by qPCR and immunoblotting, altered the subcellular distribution of biotin-HAK-3, from a typical MPR-like
perinuclear localization to a more large bubble-like structures. To study the effect of eEF1A1 knockdown on OSM-induced IL-6 expression, U343 cells grown in 24 well plates were
transfected and treated with eEF1A1-speciﬁc siRNA and OSM as described. Cells co-treated with 20 μM HAK-3 for 6 h served as positive control. The expression level of IL-6 mRNA was
measured by qRT-PCR (B), while conditioned media were used for quantiﬁcation of IL-6 release by ELISA (C). eEF1A1 knockdown signiﬁcantly reduced IL-6 mRNA expression and IL-6
secretion. The mean IL-6 protein concentration measured in OSM-stimulated mock controls was 5385.0 pg/ml. (D, E) Knockdown of eEF1A1 causes a HAK compound-like effect on
STAT3 phosphorylation at serine 727 in U343 cells. (D) Post-RNAi and OSM treatment, cell lysates (30 μg protein/lane) were separated on 4–12% SDS-polyacrylamide gels and analyzed
byWestern blotting with STAT3 and pSTAT3S727-speciﬁc antibodies (1:500, overnight). Tubulin served as a loading control. (E) Post-RNAi treatment, OSM-stimulated cells were ﬁxed in
methanol and stained with an antibody against pSTAT3S727. From each sample 15 images were taken by means of a ﬂuorescence microscope and app. 250 cells/sample were
densitometrically analyzed by MetaMorph imaging software. Mean signal intensity of mock cells was set to 100%. All data are represented as mean ± SD from experiments carried out
in triplicate. ns, not signiﬁcant; *p b 0.05; **p b 0.01; ***p b 0.001.
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is strongly supported by three outcomes: 1) The streptavidin-mediated
co-immunoprecipitation of eEF1A1 and biotin-HAK-3 indicates physical
interaction between compound and target. 2) The ability of endogenous
eEF1A1 to bind selectively biotin-HAK-3 in vitrowas demonstrated by
surface plasmon resonance. 3) The subcellular localization pattern of
bio-HAK-3 is strongly dependent on eEF1A1 expression as shown by
RNAi-mediated eEF1A1 knock-down. Interestingly, other candidates
isolated bymass spectrometry under the same experimental conditions
failed to yield comparable results. Most likely, these proteins represent
false positive targets.
One of the basic structural requirements for non-canonical functions
of eEF1A1 [45,47] is the ability to interact via phospho-tyrosine residues
with SH2 and SH3 domain-containing proteins such as sorbin,microtubule-actin cross-linking factor 1, Shp1 and Shp2 [48]. Interesting-
ly, STAT3, which was identiﬁed to be essential for HAK bioactivity, has
also a SH2 domain [49]. For the ﬁrst time, we have demonstrated that
STAT3 and eEF1A1 form complexes localized in the cellular processes.
This indicates a fundamental role of eEF1A1 in gp130/OSMRβ receptor-
mediated IL-6 transcription via binding of STAT3 at the SH2 domain.
The localization of eEF1A1 in the cell periphery appears to be a general
feature, which may be the basis for at least some of the non-canonical
functions of eEF1A1. This is supported by the demonstration of eEF1A1
recruitment to the cell membrane of NIH3T3 cells by the SAM domain
of deleted in liver cancer protein 1 (DLC1) [50]. Furthermore, eEF1A1
interacts with the PH domain of phospholipase C-gamma 1 (PLC-γ1),
which is responsible for the targeted translocation of signalingmolecules
to the cellular membrane [51]. Collectively, these data are supportive for
974 I. Schulz et al. / Biochimica et Biophysica Acta 1843 (2014) 965–975the subcellular localization of eEF1A1 reported here in human U343
glioma cells. Speciﬁc knock-down of eEF1A1 by RNAi led to a similar
suppression of OSM-induced STAT3S727 phosphorylation and transcrip-
tional inhibition of the IL-6 expression as demonstrated recently for
HAK compounds [31]. Thus, several lines of evidence demonstrate that
eEF1A1 is the relevant molecular target of the IL-6-lowering bioactivity
of HAK compounds. With respect to a proposed eEF1A1-dependent reg-
ulation of STAT3S727 phosphorylation both proteins are substrates of the
PKCδ [38,40]. PKCδ is described to be involved in the regulation of the re-
ceptor unit gp130 activity via non-classical SH2-mediated STAT3 binding
and phosphorylation at serine 727 [39]. In parallel, it was shown that
PKCδ phosphorylates eEF1A1 at threonine 431 [38], potentially affecting
the non-canonical role of eEF1A1 in IL-6 receptor signaling. In the pres-
ent work we have demonstrated for the ﬁrst time the presence of
membrane-associated complexes consisting of eEF1A1, STAT3, and
PKCδ, which strongly supports our working hypothesis of an eEF1A1-
speciﬁc kinase-regulatory function. Such kinase-regulatory functions of
eEF1A1 have already been described. For example, eEF1A1, in the GDP-
bound form, directly activates the sphingosine kinase 1 in vitro [52]. Fur-
thermore, eEF1A1 forms trimolecular complexes with the tyrosine ki-
nase Txk and PARP1, regulating an IFN-gamma promoter activity in
human Th1 cells [53]. Finally, eEF1A1 was identiﬁed as a potential bind-
ing partner for Akt2 kinase [54]. Taken all together, binding to and mod-
ulation of kinases represent a valid molecular mechanism for the non-
canonical bioactivities of eEF1A1. A simpliﬁed schematic overview on
our hypothesis of eEF1A1 involvement in OSM-induced IL-6 expression,
which is based on experimental data reported here and published by
others is given in Fig. 7. Pharmacological inhibition of eEF1A1 by HAK
compounds causes a speciﬁc suppression of STAT3S727-enhanced gene
expression. The bioactivity of HAK compounds is not exclusively limited
to gp130/OSMRβ signaling cascade, like shown recently for LPS-induced
gene expression in primary murine cells and in a septic shock mouse
model [31]. It is very likely that the non-canonical bioactivity of HAK
compounds is determined in general by eEF1A1-sensitive kinases rather
than selectively by the STAT3S727 phosphorylation step. Such a kinase-
determined bioactivity was shown for gamendazole, another non-
canonical inhibitor of eEF1A1. Gamendazole is proposed to exert its
antispermatogenic effect via negative regulation of Akt1 kinase [41]. In-
terestingly, gamendazole did not affect the GDP/GTP-binding properties,
strongly indicating that it acts as a non-canonical-selective eEF1A1Fig. 7.PostulatedmechanismofHAK-mediated suppressionofOSM-stimulated IL-6 expression i
STAT3 at serine 727. This phosphorylation event is regulated by eEF1A1 and essential for NF-κB
sion of STAT3 phosphorylation at serine 727, prevents NF-κB/STAT3 complex formation and thinhibitor. In contrast, quercetin, a canonical protein synthesis inhibitor
of eEF1A1 [55,57], produced no effect on spermatogenesis. In accordance
with this, quercetin did not suppress OSM-induced IL-6 mRNA expres-
sion in our model system (Supplementary Fig. 4). Furthermore, HAK
compounds did not show obvious effects on cell vitality, proliferation
and protein synthesis, as expected from a global canonical inhibitor of
protein biosynthesis [31]. These observations suggest that HAK com-
pounds, similar to gamendazole, target selectively non-canonical
function-related protein structures of eEF1A1. Evidence of distinct struc-
tures closely related either to canonical or non-canonical functions of
eEF1A1 supports this hypothesis [46].5. Conclusions
We identiﬁed eEF1A1 as the binding partner of STAT3 and PKCδ,
which are crucial for STAT3S727 phosphorylation and for NF-κB/STAT3-
enhanced interleukin-6 expression. Our results reveal a novelmolecular
mechanism for a non-canonical role of eEF1A1 in signal transduction
acting by direct modulation of kinase-dependent phosphorylation. For
a more detailed molecular understanding of the non-canonical role of
eEF1A1 in signal transduction and gene expression future experiments
are needed. In particular, the atomic structures that deﬁne the interac-
tion sites of kinases and small molecule drugs need to be decrypted. In
this context, it remains to be determined whether non-chemical modi-
ﬁed HAK compounds interact with eEF1A1 in a GDP/GTP independent
mode of action.
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